A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Rondo Therapeutics
Dragonfly Therapeutics
Merck Sharp & Dohme LLC
Tizona Therapeutics, Inc
Essen Biotech
Werewolf Therapeutics, Inc.
Novartis
Inhibrx Biosciences, Inc
Sairopa B.V.
Coherus Oncology, Inc.
Trishula Therapeutics, Inc.
NuCana plc
Medicenna Therapeutics, Inc.
Trishula Therapeutics, Inc.
DEKA Biosciences
GlaxoSmithKline
Carisma Therapeutics Inc
Eli Lilly and Company
Vincerx Pharma, Inc.
Simcha IL-18, Inc.
Salubris Biotherapeutics Inc
Advaxis, Inc.
Kineta Inc.
4D pharma plc
Genocea Biosciences, Inc.
Syndax Pharmaceuticals
KitovPharma